Regen BioPharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGBPP research report →
About the company
Regen BioPharma, Inc. is dedicated to advancing regenerative medicine solutions across the United States. The company's scientific endeavors involve identifying small molecules that modulate NR2F6, with the aim of either stimulating immune cells for cancer treatments or suppressing them for managing autoimmune conditions.
- CEO
- David Raymond Koos
- IPO
- 2016
- Employees
- 1
- HQ
- La Mesa, CA, US
Price Chart
- Market Cap
- $236.56K
- P/E
- -0.00
- P/S
- 0.01
- P/B
- -0.00
- EV/EBITDA
- -0.75
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -367.41%
- Net Margin
- -302.54%
- ROE
- 11.91%
- ROIC
- 19.75%
- Revenue
- $236.56K · 0.00%
- Net Income
- $-1,274,502 · -90.79%
- EPS
- $-0.05 · 66.13%
- Op Income
- $-338,540
- FCF YoY
- 44.66%
- 52W High
- $0.10
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.02
- Beta
- 0.23
- Avg Volume
- 107.47K
Get TickerSpark's AI analysis on RGBPP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our RGBPP coverage
Recent articles, reports, and earnings notes.
No research on RGBPP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RGBPP report →Similar companies
Peers in the same neighborhood.